Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.

ENTA·NASDAQ

$12.03

-6.6%
HealthcareBiotechnology

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

At a Glance

Live Snapshot
Market Cap$279.30M
EPS-3.8400
P/E Ratio-3.12
Earnings Date08/10/2026

enta

Revenue

Last Annual Value

65.32M

3-Year CAGR

-9%

5-Year CAGR

-12%

10-Year CAGR

-9%

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. Competitors Analysis of Revenue

ENTA · NASDAQ
CompanyRevenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
65.32M
-6.2%-7.6%-3.0% 
72.30M
116.1%63.2%N/A
0.00
N/AN/AN/A
39.55M
-39.2%-18.6%7.4%
0.00
N/AN/AN/A
25.42M
-41.8%N/AN/A
0.00
N/AN/AN/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
0.00
N/AN/AN/A
0.00
N/AN/AN/A
11.16M
-31.3%3.1%N/A
0.00
N/AN/AN/A
Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. Fair Value Envelope

ENTA · NASDAQ

Our analysis suggests that ENTA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.03, this represents a potential HIDDEN relative to our calculated worth for Enanta Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $12.03